Breaking Down Guizhou Bailing Group Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Guizhou Bailing Group Pharmaceutical (002424.SZ) is a bargain or a risk? In the quarter to June 30, 2025 the company posted revenue of CNY 701.39 million (down 13.42% YoY) and a trailing twelve-month revenue of CNY 3.14 billion (down 30.22% YoY), while market watchers will note a market capitalization/EV of CNY 8.07 billion / CNY 9.09 billion alongside a striking trailing P/E of 3,633.33; profitability is thin-H1 net income of CNY 51.83 million (vs CNY 87.46M a year ago), an operating margin of 1.83% and net profit margin near 0.19%-and liquidity and solvency metrics raise flags (current ratio 0.99, quick ratio 0.62, Altman Z-Score 2.19, debt-to-equity 0.36) even as operating cash flow and free cash flow remain positive and the stock has climbed +37.44% over 52 weeks-read on to parse valuation, risk factors, and whether these mixed signals point to opportunity or caution.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Revenue Analysis

• Quarter (Q2 2025, ended Jun 30): Revenue CNY 701.39 million (down 13.42% YoY).
• Trailing Twelve Months (TTM): Revenue CNY 3.14 billion (down 30.22% YoY).
• Full year 2024: Revenue CNY 3.83 billion (down 10.26% vs. 2023).
• Employees: 6,586; revenue per employee ≈ CNY 477,460.
• Market capitalization: CNY 7.40 billion; Price-to-Sales (P/S): 2.35.

• Trend interpretation: revenues have declined on multiple horizons (quarterly, TTM, and FY2024), indicating challenges in sustaining sales momentum.
• Operational efficiency metric: revenue per employee (~CNY 477k) provides a workforce productivity snapshot to compare with peers.
• Valuation lens: P/S of 2.35 on a CNY 7.40 billion market cap contextualizes investor expectations against shrinking sales.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Profitability Metrics

For the half-year ended June 30, 2025, Guizhou Bailing Group Pharmaceutical Co., Ltd. reported a clear deterioration in core profitability indicators versus the same period in 2024. Key headline figures highlight compressed margins, declining EPS and very low returns on equity.

• Net income fell by CNY 35.63 million year-over-year for the half-year period (from CNY 87.46M to CNY 51.83M).
• Basic EPS from continuing operations declined from CNY 0.06 to CNY 0.04, and TTM EPS is effectively zero (CNY 0.00).
• ROE at 0.24% signals minimal earnings generated from shareholders' equity.
• Operating margin (1.83%) and profit margin (0.07%) indicate earnings are largely consumed by operating costs and non-operating items.
• Net profit margin of 0.19% shows limited conversion of revenue into net income.

For historical context on the company's strategy, ownership and business model, see: Guizhou Bailing Group Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Debt vs. Equity Structure

Key balance-sheet and leverage metrics for Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) point to a moderate leverage profile but notable short-term liquidity pressure and limited ability to cover interest from operating earnings.

• Total debt: CNY 1.19 billion
• Debt-to-equity ratio: 0.36 (moderate leverage)
• Net cash position: -CNY 1.01 billion (negative net cash / net debt)
• Net debt per share: -CNY 0.74
• Current ratio: 0.99 (current liabilities ≈ current assets)
• Quick ratio: 0.62 (limited short-term liquid cover)
• Interest coverage ratio: 0.89 (EBIT below interest expense)

• Liquidity signal: Current and quick ratios below or near 1.0 suggest working-capital stress and limited buffer for unexpected cash needs.
• Coverage risk: Interest coverage below 1.0 implies the company may need to draw on cash reserves, refinance, or access external funding to meet interest payments.
• Leverage context: A debt-to-equity ratio of 0.36 is not high in isolation, but combined with negative net cash and weak coverage metrics it warrants caution.

For additional investor context and shareholder activity, see: Exploring Guizhou Bailing Group Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Liquidity and Solvency

Key liquidity and solvency indicators for Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) reveal a mix of solid cash-generation capacity, modest short-term liquidity pressure, and moderate bankruptcy risk metrics. Below are the principal figures and what they imply for investors.

• Operating cash flow (TTM): CNY 588.04 million
• Capital expenditures (TTM): CNY 9.10 million
• Free cash flow (OCF - CapEx, reported): CNY 597.14 million
• Working capital: -CNY 30.38 million (slight short-term liquidity deficit)
• Altman Z-Score: 2.19 (moderate risk of bankruptcy)
• Piotroski F-Score: 5 (average financial health)
• Beta: 0.50 (lower volatility vs. the market)
• 52‑week price change: +37.44% (positive equity performance)

Investors should weigh the company's strong free cash flow and low capex against the negative working capital and middling credit-risk metrics. For broader context on the company's background, strategy, and how it makes money, see: Guizhou Bailing Group Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Valuation Analysis

• Trailing P/E: 3,633.33 - indicates market price far outpaces reported earnings per share.
• P/B: 2.46 - stock trades at ~2.5× book value, a premium to net asset base.
• EV/EBITDA: 52.60 - implies an expensive valuation relative to operating cash profits.
• EV/Free Cash Flow: 15.23 - enterprise value is ~15× free cash flow, signaling valuation pressure vs. cash generation.
• P/S: 2.56 - moderate pricing versus revenue, not as extreme as earnings multiples.
• Market Cap: CNY 8.07 billion; Enterprise Value: CNY 9.09 billion.

• Extremely high P/E (3,633.33) commonly reflects very low or negative recent EPS - investors should review the latest income statement for one-offs, tax effects, or discontinued operations.
• EV/EBITDA of 52.60 suggests market pricing assumes substantial future margin expansion or earnings recovery; compare to peer group EV/EBITDA to gauge premium.
• EV/FCF at 15.23 is closer to traditional valuation bands but still requires reliable cash-conversion forecasts to be comfortable.
• P/B of 2.46 and P/S of 2.56 indicate the market prices both assets and sales at premiums; check asset quality, intangible balances, and revenue sustainability.
• Market cap vs. enterprise value spread (~CNY 1.02 billion) signals net debt/minority exposure - review balance sheet for leverage and off-balance items.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Risk Factors

• Intense market competition: The firm operates in a crowded Chinese pharmaceutical market with strong domestic and multinational players, which can pressure pricing, market share and R&D returns.
• Thin profitability: Operating margin of 1.83% and net profit margin of 0.07% indicate very slim earnings relative to revenue, leaving limited buffers for adverse events or increased costs.
• Liquidity constraints: Current ratio of 0.99 and quick ratio of 0.62 suggest limited short-term liquidity headroom, raising the possibility of difficulty meeting near-term obligations without asset sales or new financing.
• Leverage considerations: Debt-to-equity ratio of 0.36 signals moderate leverage - manageable in stable conditions but potentially risky if cash flows weaken.
• Bankruptcy risk signal: An Altman Z-Score of 2.19 places the company in a moderate-risk zone, implying financial distress is not imminent but should be monitored.
• Mixed fundamental quality: Piotroski F-Score of 5 points to average financial strength and operational performance, indicating room for improvement in profitability, efficiency, and capital structure metrics.

• Pricing pressure and margin erosion from competitors and generics.
• R&D productivity and successful commercialization of new drugs.
• Working capital management given near-unit current ratio and low quick ratio.
• Access to affordable financing if revenues or cash flows decline.
• Regulatory changes in China affecting drug approvals, reimbursement and procurement.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Growth Opportunities

• Market capitalization of CNY 8.07 billion and enterprise value of CNY 9.09 billion - a manageable EV/Market Cap spread that supports M&A or capital expenditure flexibility.
• TTM revenue of CNY 3.14 billion vs. TTM net income of CNY 2.22 million - indicates substantial room to convert top-line growth into meaningful bottom-line profits through cost control, product mix optimization, and higher-margin offerings.
• Beta of 0.50 - lower volatility relative to the broader market, attractive for risk-averse investors seeking pharmaceutical exposure with reduced share-price swings.
• 52-week price change of +37.44% - demonstrates strong recent market performance and investor appetite, which can aid capital raising and partner negotiations.
• P/B ratio of 2.46 and P/S ratio of 2.56 - trading at a premium to book and a moderate sales multiple, suggesting market confidence while leaving room for valuation expansion if execution improves.

• Revenue growth levers: geographic expansion, increased penetration of existing therapeutic areas, licensing or co-promotion deals to accelerate sales without proportional fixed-cost increases.
• Profitability levers: margin expansion via manufacturing efficiencies, vertical integration, portfolio rationalization toward higher-margin products, and tighter SG&A control.
• Capital and valuation strategy: leverage favorable stock momentum (52-week +37.44%) and moderate valuation multiples to raise capital for strategic R&D, bolt-on acquisitions, or capacity upgrades.
• Risk management: maintain conservative leverage given EV/Market Cap dynamics and preserve the lower volatility profile (beta 0.50) to attract institutional long-only and income-focused investors.